Overview

HMPL-760 Safety and Tolerability Study in Patients With Previously Treated CLL/SLL or NHL

Status:
Not yet recruiting
Trial end date:
2025-10-30
Target enrollment:
Participant gender:
Summary
An open label single-arm clinical trial to evaluate the safety, tolerability, PK, PD, and preliminary efficacy of HMPL-760 in patients with previously treated CLL/SLL or NHL
Phase:
Phase 1
Details
Lead Sponsor:
Hutchison Medipharma Limited